"Pirenzepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Descriptor ID |
D010890
|
MeSH Number(s) |
D03.633.100.079.080.070.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pirenzepine".
Below are MeSH descriptors whose meaning is more specific than "Pirenzepine".
This graph shows the total number of publications written about "Pirenzepine" by people in this website by year, and whether "Pirenzepine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2003 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pirenzepine" by people in Profiles.
-
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003 Nov 26; 290(20):2693-702.
-
Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003 Oct; 160(10):1817-22.
-
Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50.
-
Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999 Feb; 60(2):116-8.
-
Kumra S, Jacobsen LK, Lenane M, Karp BI, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry. 1998 Apr; 37(4):377-85.
-
Lucchesi PA, Romano FD, Scheid CR, Yamaguchi H, Honeyman TW. Interaction of agonists and selective antagonists with gastric smooth muscle muscarinic receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb; 339(1-2):145-51.